Loading clinical trials...

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356•Allergan

View on ClinicalTrials.gov

Summary

A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).

Eligibility

Age

35 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Qualified to receive treatment with BOTOX® Cosmetic, a facial filler (JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA Plus XC and/or JUVÉDERM® VOLUMA® XC) and LATISSE® treatment
•Naïve to botulinum toxin therapy of any serotype for any indication
•Naïve to prescription eyelash growth products of any type
•Naïve to dermal filler treatment in the face and neck

Exclusion Criteria

•Undergone facial plastic surgery, tissue grafting, tissue augmentation or facial dermal filler injections
•Had laser, photomodulation, intense pulsed light, radio frequency, dermabrasion or chemical peel in the face or neck
•Have received skin resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or non-ablative procedures) in the face or neck within 3 months
•Systemic retinoid therapy within 1 year prior to study enrollment
•Presence of inflammation at the proposed injection site(s)
•Profound atrophy/excessive weakness of muscles in target areas of injection
•Known immunization or hypersensitivity to any botulinum toxin serotype
•Undergone oral surgery or dental procedures within 30 days
•No visible eyelashes
•Use of permanent eyeliner, eyelash implants, semi-permanent eyelash tint, dye or extension
+3 more criteria

Locations (1)

Los Angeles, California, United States

Key Dates

Start Date

June 30, 2014

Primary Completion Date

May 3, 2015

Completion Date

May 3, 2015

Last Updated

January 9, 2019

Enrollment

116

ACTUAL participants

Conditions

Facial RhytidesCrow's Feet LinesGlabellar LinesNasolabial Fold

Interventions

onabotulinumtoxinA

BIOLOGICAL

bimatoprost ophthalmic solution 0.03%

DRUG

JUVÉDERM® ULTRA XC

DEVICE

JUVÉDERM® ULTRA PLUS XC

DEVICE

JUVÉDERM® VOLUMA® XC

DEVICE

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement